<DOC>
	<DOC>NCT00481325</DOC>
	<brief_summary>The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder</brief_summary>
	<brief_title>Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Outpatient women ages 1865 meeting Diagnostic and Statistical Manual of Mental Disorders Manual, Fourth Edition, Text Revision (DSMIV TR) criteria for Generalized Anxiety Disorder (GAD), either moderate or severe (300.02) Males Patients who report a history of inadequate response to three or more adequate trials of any selective Serotonin reuptake inhibitors (SSRIs) for GAD within the last three years</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>